|
|
|
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
|
Title of each class
|
Trade
Symbol(s)
|
Name of each exchange
on which registered
|
||
|
|
|
|
| (a) |
Financial statements of business acquired
|
| (b) |
Pro forma financial information
|
| (d) |
Exhibits
|
|
Exhibit
Number
|
Description
|
|
|
Agreement and Plan of Merger, dated September 17, 2026, by and among Lisata Therapeutics, Inc., Mariner Merger Sub I, Inc., Mariner Merger Sub
II, LLC and Marea Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
|
||
|
Certificate of Designation of Series C Non-Voting Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No.
001-33650) filed with the SEC on September 17, 2026).
|
||
|
Form of Marea Stockholders Registration Rights Agreement, by and among Lisata Therapeutics, Inc. and certain Marea stockholders
(incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
|
||
|
Form of Securities Purchase Agreement, dated as of September 17, 2026, by and among Lisata Therapeutics, Inc. and each investor
listed on Exhibit A thereto (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
|
||
|
Form of Registration Rights Agreement, by and among Lisata Therapeutics, Inc. and certain investors signatory thereto (incorporated by
reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
|
||
|
Consent of Ernst & Young LLP, Independent Auditors.
|
|
Press Release issued on September 17, 2026 (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September
17, 2026).
|
||
|
Presentation made available to the Investors by Lisata Therapeutics, Inc. and Marea Therapeutics, Inc. on September 17, 2026
(incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K (File No. 001-33650) filed with the SEC on September 17, 2026).
|
||
|
Audited Combined Financial Statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. as of and for the years ended December 31, 2025 and 2024 and the related notes thereto.
|
||
|
Unaudited Condensed Combined Interim Financial Statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. as of June 30, 2026 and December 31, 2025 and for the six months ended June 30, 2026 and 2025
and the related notes thereto.
|
||
|
Unaudited Pro Forma Combined Interim Financial Information of the Company as of and for the six months ended June 30, 2026 and the year ended December 31, 2025.
|
||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
Lisata Therapeutics, Inc.
|
||
|
Date: November 12, 2026
|
By:
|
/s/ David J. Mazzo, Ph.D.
|
|
David J. Mazzo, Ph.D.
|
||
|
Chief Executive Officer
|
||